Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Avalon Charts. Click Here for more Avalon Charts.](/p.php?pid=staticchart&s=N%5EAVRX&p=8&t=15)
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that Kenneth
C. Carter, Ph.D., President and CEO, will provide an update on the
Company at the BIO CEO & Investor Conference.
The conference will be held at the Waldorf-Astoria Hotel in New York
from February 11-13. Dr. Carter is scheduled to present on Monday,
February 11, at 3:30pm.
The presentation will be available live via webcast and can be accessed
through the Investor Presentations section of Avalon Pharmaceuticals’
website, http://www.avalonrx.com,
or go directly to the webcast via the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AVRX&item_
id=1752233. (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the
extra space if one exists.) An archive of the presentation will be
available for 90 days following the conference.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer therapeutics.
Avalon’s lead product candidate, AVN944, an
IMPDH inhibitor, is in Phase II clinical development. Avalon also has
preclinical programs to develop inhibitors of the Beta-catenin and
Aurora/Centrosome pathways, discovery programs for inhibitors of the
Survivin and Myc pathways and partnerships with Merck, MedImmune,
ChemDiv, Medarex, and Novartis. AvalonRx®
is the company’s proprietary platform which is
based on large-scale biomarker identification and monitoring, used to
discover and develop therapeutics for pathways that have historically
been characterized as "undruggable." Avalon is headquartered in
Germantown, MD.
Safe Harbor Statement
This announcement contains, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties.
Such statements reflect the current views of Avalon management and are
based on certain assumptions. Actual results could differ materially
from those currently anticipated as a result of a number of factors,
risks and uncertainties, including those specified under the “Risk
Factors” section of our 2006 Annual Report on
Form 10-K and updates contained in subsequent filings we make with the
Securities and Exchange Commission.